Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Global Market Value Of The Granulomatosis With Polyangiitis Treatment Industry In 2025?
The granulomatosis with polyangiitis treatment market size has witnessed substantial growth in recent years. This market is projected to expand from $2.36 billion in 2024 to $2.55 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.9%. This historical expansion can be attributed to several factors, including an escalating need for the drugs, a rising number of clinical trials, increased demand for effective treatment, a growing emphasis on personalized medicine, and improved diagnosis rates of the disorder.
The granulomatosis with polyangiitis treatment market size is projected to experience robust expansion over the coming years. By 2029, it is anticipated to reach $3.44 billion, driven by a compound annual growth rate (CAGR) of 7.8%. This growth throughout the forecast period stems from factors such as the increasing occurrence of autoimmune diseases, the growing prevalence of granulomatosis, a rise in polyangiitis incidences, and an uptick in immunological disorders. Key trends shaping the forecast period encompass progress in drug development, developments within the healthcare sector, enhancements in diagnostic methodologies, improved treatment alternatives, and the emergence of biologics and biosimilars.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21196&type=smp
Which Drivers Are Shaping The Granulomatosis With Polyangiitis Treatment Industry’s Market Share?
The rising incidence of autoimmune conditions is anticipated to drive expansion in the granulomatosis with polyangiitis treatment market. These diseases develop when the immune system erroneously targets the body’s own healthy components, resulting in inflammation and harm across different organs. The growing occurrence of autoimmune diseases stems from environmental factors, including infections, chemicals, or pollutants, alongside evolving lifestyle habits. Treatment for granulomatosis with polyangiitis offers benefits for autoimmune diseases through immunosuppressive agents like corticosteroids and cyclophosphamide. These agents are effective in managing inflammation and preventing organ damage, highlighting the importance of timely and customized therapeutic approaches for other autoimmune conditions with comparable underlying processes. A relevant example is found in a June 2023 report from the Office for National Statistics, a UK government body, which indicated that the worldwide count of individuals living with multiple sclerosis (MS), an autoimmune disease, reached 2.9 million in 2023, an increase from 2.8 million in 2022. Consequently, the expanding presence of autoimmune diseases is propelling the growth of the granulomatosis with polyangiitis treatment market.
What Are The Key Segments In The Granulomatosis With Polyangiitis Treatment Market?
The granulomatosis with polyangiitis treatmentmarket covered in this report is segmented –
1) By Drug Type: Steroids; Immunosuppressant; Other Drug Types
2) By Treatment Type: Immunosuppressants; Corticosteroids
3) By Route Of Administration: Oral; Intravenous
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Steroids: Prednisone; Methylprednisolone; Dexamethasone; Hydrocortisone
2) By Immunosuppressants: Cyclophosphamide; Methotrexate; Azathioprine; Mycophenolate mofetil; Rituximab
3) By Other Drug Types: Plasma Exchange Therapy; Intravenous Immunoglobulin (IVIG); Biologic Agents; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Which Trends Are Impacting The Granulomatosis With Polyangiitis Treatment Market?
Leading companies in the granulomatosis with polyangiitis treatment market are prioritizing the creation of innovative products, such as oral corticosteroids, to provide patients with enhanced treatment solutions that facilitate better control of the disease while reducing the prolonged adverse effects of steroid use. Oral corticosteroids are drugs designed to diminish inflammation and modulate the immune response, frequently prescribed for allergies, autoimmune conditions, and inflammatory disorders. An example occurred in October 2024 when AstraZeneca plc, a UK-based pharmaceutical company, revealed that Fasenra (bevacizumab) received approval in the European Union, a Europe-based political and economic union of European countries, for adjunctive therapy in adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This endorsement resulted from favorable outcomes of the MANDARA Phase III trial, which showed Fasenra’s effectiveness in reaching remission and lessening the need for oral corticosteroids in EGPA patients.
Who Are The Major Companies Operating In The Granulomatosis With Polyangiitis Treatment Market?
Major companies operating in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech Inc., Incyte Corporation, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ChemoCentryx Inc., Medac Pharma Inc., InflaRx GmbH
Download The Full Report For Exclusive Market Findings:
What Are The Regional Market Dynamics Impacting The Granulomatosis With Polyangiitis Treatment Industry?
North America was the largest region in the granulomatosis with polyangiitis treatment market in 2024. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Granulomatosis With Polyangiitis Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21196&type=smp
Browse Through More Reports Similar to the Global Granulomatosis With Polyangiitis Treatment Market 2025, By The Business Research Company
Fertility Treatments Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report
Polycystic Ovarian Syndrome Treatment Global Market Report 2025
Alzheimer Disease Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model